Literature DB >> 11395133

Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.

W S Meng1, L H Butterfield, A Ribas, J B Heller, V B Dissette, J A Glaspy, W H McBride, J S Economou.   

Abstract

Human alpha-fetoprotein (AFP) is a potentially important target for the immunotherapy of hepatocellular carcinoma (HCC). AFP(542-550) (GVALQTMKQ) is one of several HLA-A2.1-restricted immunodominant AFP peptides that consistently generate AFP-specific T cell responses in human T cell cultures and in HLA-A2.1/K(b) transgenic (A2.1 tg) mice. We performed a fine specificity analysis of this nonamer to determine which amino acid side chains were critical for T cell priming and recognition. Using peptide-pulsed dendritic cells (DC) as an immunization strategy, we characterized the effects of AFP(542-550) amino acid substitutions on priming and recognition in A2.1 tg mice. Replacing the glutamine at anchor position 9 with a leucine enhanced MHC binding and AFP-specific T cell responses. Substitution of leucine at non-anchor position 4 with an alanine did not alter binding but greatly diminished T cell recognition. Computer-generated three-dimensional models provided the structural rationale for these observed effects in MHC binding and T cell responses resulted from the modifications in the AFP(542-550) sequence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11395133     DOI: 10.1016/s0161-5890(01)00017-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  19 in total

Review 1.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

2.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

3.  Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Authors:  Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

4.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

5.  Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.

Authors:  Yang Liu; Sean Daley; Viktoria N Evdokimova; David D Zdobinski; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 6.  Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Authors:  Yukai He; Yuan Hong; Gerald J Mizejewski
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma.

Authors:  Shahriar Behboudi; Stephen P Pereira
Journal:  World J Hepatol       Date:  2010-07-27

8.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

9.  Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70.

Authors:  Xiao-Ping Wang; Guo-Zhen Liu; Ai-Li Song; Hai-Yan Li; Yu Liu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

10.  Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.

Authors:  S Behboudi; A Alisa; S Boswell; J Anastassiou; A A Pathan; R Williams
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.